Price_2002_Age.Ageing_31_307

Reference

Title : An N-of-1 randomized controlled trial ('N-of-1 trial') of donepezil in the treatment of non-progressive amnestic syndrome - Price_2002_Age.Ageing_31_307
Author(s) : Price JD , Grimley Evans J
Ref : Age Ageing , 31 :307 , 2002
Abstract :

INTRODUCTION: a professional man sustained a residual, persisting, isolated impairment of short-term memory secondary to severe carbon monoxide poisoning. Informal, open trial of the cholinesterase inhibitor donepezil resulted in uncertain benefit. PROTOCOL: an N-of-1 randomized, double-blind controlled trial of donepezil against placebo. Placebo-induced headache permitted evaluation of donepezil at only the 5 mg dose. RESULTS: there was no improvement in short-term memory. CONCLUSION: the trial excluded significant benefit of donepezil 5 mg in this patient, preventing long-term unnecessary prescription. Beneficial effects in other similar patients or at higher dosage cannot be excluded.

PubMedSearch : Price_2002_Age.Ageing_31_307
PubMedID: 12147570

Related information

Citations formats

Price JD, Grimley Evans J (2002)
An N-of-1 randomized controlled trial ('N-of-1 trial') of donepezil in the treatment of non-progressive amnestic syndrome
Age Ageing 31 :307

Price JD, Grimley Evans J (2002)
Age Ageing 31 :307